Jason V Baker

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center HCMC, Minneapolis, Minnesota, USA
    PLoS ONE 7:e46894. 2012
  2. ncbi HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 60:128-34. 2012
  3. ncbi Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 56:36-43. 2011
  4. ncbi Cardiovascular implications from untreated human immunodeficiency virus infection
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, University of Minnesota, 701 Park Ave, MC G5, Minneapolis, MN 55415, USA
    Eur Heart J 32:945-51. 2011
  5. ncbi Biomarkers and HIV-associated cardiovascular disease
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55415, USA
    Curr Opin HIV AIDS 5:511-6. 2010
  6. ncbi Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 25:2133-42. 2011
  7. ncbi Untreated HIV infection and large and small artery elasticity
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 52:25-31. 2009
  8. ncbi The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms
    Jason V Baker
    University of Minnesota, Hennepin County Medical Center, Minneapolis, Minnesota, USA
    Curr Opin HIV AIDS 4:176-82. 2009
  9. ncbi Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases
    Jason V Baker
    Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 48:541-6. 2008
  10. ncbi CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 22:841-8. 2008

Detail Information

Publications17

  1. ncbi Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center HCMC, Minneapolis, Minnesota, USA
    PLoS ONE 7:e46894. 2012
    ..Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed...
  2. ncbi HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 60:128-34. 2012
    ..Understanding the effects of HIV replication on endothelial dysfunction and platelet activation may identify treatment targets to reduce cardiovascular disease risk...
  3. ncbi Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 56:36-43. 2011
    ..Changes in these biomarkers have been described after stopping ART, but not after starting ART in SMART...
  4. ncbi Cardiovascular implications from untreated human immunodeficiency virus infection
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, University of Minnesota, 701 Park Ave, MC G5, Minneapolis, MN 55415, USA
    Eur Heart J 32:945-51. 2011
    ..Ultimately, additional adjunctive treatment will be needed to mitigate premature CVD risk among contemporary HIV-infected patients with access to ART...
  5. ncbi Biomarkers and HIV-associated cardiovascular disease
    Jason V Baker
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55415, USA
    Curr Opin HIV AIDS 5:511-6. 2010
    ..Our goal is to summarize recent literature on biomarkers of cardiovascular disease (CVD) in the setting of HIV infection with an emphasis on those associated with clinical events...
  6. ncbi Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 25:2133-42. 2011
    ..The effects of initiating versus deferring ART on high-density and low-density lipoprotein particle (HDL-P and LDL-P, respectively) concentrations and apolipoprotein (Apo) levels are not well described...
  7. ncbi Untreated HIV infection and large and small artery elasticity
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    J Acquir Immune Defic Syndr 52:25-31. 2009
    ..Untreated HIV infection may increase risk for cardiovascular disease, and arterial elasticity is a marker of cardiovascular risk and early disease...
  8. ncbi The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms
    Jason V Baker
    University of Minnesota, Hennepin County Medical Center, Minneapolis, Minnesota, USA
    Curr Opin HIV AIDS 4:176-82. 2009
    ..e. at higher CD4 cell counts than currently recommended by guidelines)...
  9. ncbi Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases
    Jason V Baker
    Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 48:541-6. 2008
    ..Low CD4+ increases risk for both AIDS- and non-AIDS-related morbidity and mortality. The magnitude of CD4+ recovery early after initial antiretroviral therapy (ART) is important in the ultimate duration of immune depletion...
  10. ncbi CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 22:841-8. 2008
    ..Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients...
  11. ncbi Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection
    Jacqueline Neuhaus
    University of Minnesota, Minneapolis, Minnesota 55414, USA
    J Infect Dis 201:1788-95. 2010
    ..Human immunodeficiency virus (HIV) replication and immune activation may increase inflammation and coagulation biomarkers. Limited data exist comparing such biomarkers in persons with and without HIV infection...
  12. ncbi Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
    David R Boulware
    University of Minnesota, Minneapolis, Minnesota, USA
    J Infect Dis 203:1637-46. 2011
    ..Substantial morbidity occurs during the first year of antiretroviral therapy (ART) in persons with advanced human immunodeficiency virus (HIV) disease despite HIV suppression. Biomarkers may identify high-risk groups...
  13. ncbi Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study
    Sonja M Bjerk
    Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America
    PLoS ONE 8:e56249. 2013
    ..Studies of biomarker associations with bacterial pneumonia risk in treated HIV-infected patients do not currently exist...
  14. ncbi Collagen deposition limits immune reconstitution in the gut
    Jacob Estes
    Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Infect Dis 198:456-64. 2008
    ....
  15. ncbi Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort
    Jason V Baker
    Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, USA
    Clin Infect Dis 53:826-35. 2011
    ..Persons with human immunodeficiency virus (HIV) infection are at risk for premature cardiovascular disease (CVD). Predictors of atherosclerotic disease progression in contemporary patients have not been well described...
  16. ncbi Inguinal lymph node biopsy in patients infected with the human immunodeficiency virus is safe
    David E Skarda
    Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
    Surg Infect (Larchmt) 8:173-8. 2007
    ..Additionally, we monitored the rates of other complications, namely, hematoma, dorsal vein thrombosis, epididymitis, lymphocele, and suture extrusion...
  17. ncbi A case for treating high hepatitis B DNA levels before starting HIV therapy
    Jason V Baker
    AIDS 20:2402-3. 2006